SLIM Films Tirzepatide 5mg

Quantity	1 x 4, 2 x 4, 3 x 4, 4 x 4, 5 x 4, 6 x 4

SLIM Films Tirzepatide 5mg — Dual GIP/GLP-1 Buccal Films for Weight Management Support

This is a compounded medicine — mucoadhesive buccal films containing tirzepatide 5mg (a dual GIP and GLP-1 receptor agonist), designed to be placed against the inner cheek and left to dissolve.

So each film delivers tirzepatide directly through the buccal mucosa, bypassing the digestive system entirely. As a result, SLIM Films Tirzepatide 5mg offer a needle-free option for adults who have used or would suit Mounjaro-style dual-receptor therapy, providing ongoing weight management support without the practical burdens of weekly subcutaneous injections.

Tirzepatide’s dual mechanism (targeting both GIP and GLP-1 receptors) is pharmacologically different from semaglutide’s single GLP-1 receptor action.

So this product fits patients who specifically want or need the tirzepatide mechanism rather than semaglutide alternatives.

Important: this is an unlicensed compounded medicine, and tirzepatide has genuine cardiovascular, pancreatitis, and thyroid contraindications. So prescriber assessment is essential before supply. Available at Medical Mojo after full clinical review.

At Medical Mojo, we believe in treatment that fits the person, but only where it’s honest, safe, and consented to.

This page covers what SLIM Films Tirzepatide 5mg are, how the dual GIP/GLP-1 mechanism differs from semaglutide alternatives, who they may suit, how they compare to Mounjaro injections and other buccal options, and the practical points that matter — including realistic clinical positioning, tirzepatide-specific safety considerations, and when injection continuation might suit better.

Regulatory position — please read first

Before going further, we want to be straight with you about four things:

First, SLIM Films Tirzepatide 5mg are an unlicensed compounded medicine manufactured to prescriber order under GPhC-regulated compounding standards by our compounding partner APC Labs Ltd (GPhC 9012301, Southampton). So they aren’t licensed medicines like Mounjaro or Zepbound. Instead, they’re compounded medicines made available under the compounding pathway where a prescriber judges an alternative formulation is needed to meet a specific clinical need.

Second, tirzepatide is pharmacologically different from semaglutide. Whereas semaglutide targets only the GLP-1 receptor, tirzepatide targets both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). This dual mechanism is why tirzepatide often produces greater weight loss than semaglutide in head-to-head trials. So the choice between tirzepatide and semaglutide isn’t trivial — it reflects specific pharmacological differences with meaningful clinical implications.

Third, tirzepatide has important safety considerations. Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous pancreatitis, severe gastrointestinal disease, and pregnancy are all reasons tirzepatide can’t be used. So our prescriber assesses these before first supply, and side effects (particularly gastrointestinal) may be prominent.

Fourth, the evidence base for buccal tirzepatide specifically is limited. While tirzepatide itself has extensive evidence (SURMOUNT trials for weight management, SURPASS trials for diabetes), the buccal delivery format has less specific clinical trial data compared to subcutaneous injection. As a result, our prescriber discusses what this means for realistic expectations, dose response variability, and monitoring approach before supply.

If any of these points raise concerns, please talk to our prescriber before proceeding. After all, dual receptor GLP-1/GIP therapy needs proper clinical judgement, not just prescription fulfilment.

Five key takeaways

SLIM Films Tirzepatide 5mg are a compounded medicine — mucoadhesive buccal films of tirzepatide 5mg made by GPhC-regulated compounding partner APC Labs to individual prescriber order. Provides tirzepatide’s dual GIP/GLP-1 mechanism in a needle-free format
Same buccal delivery format as SLIM Films semaglutide range. Films adhere to the inner cheek, dissolve over minutes, and deliver tirzepatide through the buccal mucosa into systemic circulation, bypassing gastric degradation entirely. Uses the Novafilm base with menthol as a permeation enhancer
Dual receptor mechanism (GLP-1 and GIP) is pharmacologically different from semaglutide’s single GLP-1 receptor action. SURMOUNT trials showed tirzepatide often produces greater weight loss than semaglutide in comparable patient populations. Suits patients who specifically want or need this mechanism
Same practical advantages as semaglutide SLIM Films — needle-free option, no cold chain required, discreet and portable, no injection technique needed. Films dissolve in the mouth without water. Suitable for vegetarians (Novafilm base contains no animal-derived ingredients)
Tirzepatide side effects (particularly nausea, vomiting, and diarrhoea) may be prominent, especially initially. Contraindications include medullary thyroid carcinoma, MEN2 syndrome, previous pancreatitis, pregnancy, breastfeeding. Prescriber assessment before supply is essential, not optional

Why choose Medical Mojo for tirzepatide support

At Medical Mojo, our approach starts with a simple idea: treatment should fit the person, not force the person to fit the system.

Dr Rosalind Jex

Our service is shaped by the philosophy of Dr Rosalind Jex, our brand pharmacist.

Dr Rosalind represents the spirit of the pharmacy: evidence-led, community-rooted, and willing to challenge the one-size-fits-all approach to medicine. She is named in honour of two pioneering women in science: Rosalind Franklin, the chemist and X-ray crystallographer whose work revealed the structure of DNA; and Sophia Jex-Blake, the first female doctor in the UK, who fought the medical establishment for the right to practise.

In her steampunk laboratory, Dr Rosalind works against pharma’s standardised approach to medicine. In the real world, she represents what we stand for. Her view is straightforward: you are not broken. The system is. And we are here to change that.

The maintenance phase deserves proper attention

Most weight management services stop paying attention once the weight has come off. Medical Mojo is different. So we recognise that:

The maintenance phase is where most weight management fails
Patients are often discharged at exactly the point support matters most
Weight regain after stopping GLP-1 therapy is the expected pattern, not the exception
Ongoing support should be proportionate, not maximal
The lowest effective level of support is usually the right target
Some patients need no ongoing therapy at all, and we’ll say so
Prescriber judgement about intensity matters

Mechanism choice deserves proper consideration

Not every patient responds the same way to different actives. Medical Mojo is different. So we recognise that:

Tirzepatide and semaglutide are pharmacologically different molecules
Some patients respond better to one than the other
Some patients tolerate one better than the other
Individual factors including diabetes status, weight loss history, and tolerance patterns matter
Getting the right mechanism matters more than defaulting to whichever is newest or most talked about
Prescriber judgement about mechanism preference matters

Honest framing about tirzepatide vs semaglutide

Different molecules, different profiles:

Tirzepatide often produces greater weight loss than semaglutide in head-to-head trials
However, individual response varies significantly
Tirzepatide has shorter post-marketing safety history than semaglutide
GI side effects (particularly diarrhoea) may be more prominent with tirzepatide
Hair thinning reported more with tirzepatide
Oral contraceptive interaction is tirzepatide-specific
Choice should reflect individual clinical situation, not just newest option

Honest framing about tirzepatide vs injection continuation

Different delivery, meaningful differences:

Buccal tirzepatide provides needle-free ongoing mechanism support
However, it isn’t equivalent to full 5-15mg weekly Mounjaro injection
Injection continuation has stronger evidence base
Injection continuation provides more consistent plasma concentrations
SLIM Films Tirzepatide fit needle-free preference at ongoing-support-intensity dose
If actively losing weight, continued injection therapy usually fits better

Honest framing about GIP receptor addition

What the dual mechanism actually means:

GIP receptor engagement adds a second incretin pathway
This produces meaningfully different pharmacology than GLP-1 alone
Clinical translation: greater weight loss in head-to-head trials
May improve tolerability of GLP-1 activation for some patients
Not all patients need or benefit from GIP addition
Semaglutide alternatives remain appropriate for many patients

Honest framing about GLP-1/GIP discontinuation and weight regain

The data:

SURMOUNT-4 trial showed patients regained substantial weight after stopping tirzepatide
STEP 1 extension: patients regained approximately two-thirds of weight lost within a year of stopping semaglutide
This isn’t a treatment failure, it reflects the chronic nature of obesity biology
Obesity is now understood as a chronic condition needing ongoing management
Many patients need long-term or intermittent pharmacological support
Some patients successfully transition to lifestyle-only maintenance
Individual factors matter significantly

Honest framing about the compounded medicine status

What this means:

SLIM Films are unlicensed compounded medicines, not licensed medicines like Mounjaro or Zepbound
Made under GPhC-regulated compounding manufacturing standards
Individual prescriber judgement basis for supply
Less specific evidence base than licensed products
MHRA regulates unlicensed compounded medicines differently from licensed products
The compounding pathway exists precisely because alternative formulations meet specific clinical needs
However, licensed products preferred where they meet the need

Tirzepatide and the bigger picture

Weight management rarely sits in isolation. So our prescriber can discuss:

Comprehensive approach
Dietary patterns that sustain outcomes
Physical activity for weight management
Sleep quality and weight regulation
Stress and emotional eating
Menstrual cycle and hormonal factors
Menopause and weight regulation
Cardiovascular risk maintenance benefits
Metabolic markers monitoring
Contraception considerations (tirzepatide-specific)
Nutritional support (particularly for hair health)
When to consider dose adjustment
When to transition off pharmacological support
When to consider return to injection therapy

Sometimes weight maintenance is one part of a wider health picture worth talking through.

Prescriber support before and after supply

Our team is here to discuss:

Whether SLIM Films Tirzepatide fit your specific situation
Whether semaglutide alternatives would suit equally
Alternative approaches
Comprehensive lifestyle work alongside pharmacological support
Correct application technique
Realistic expectations
Monitoring approach
Contraception considerations if relevant
What to do if you don’t feel enough effect
What to do if side effects are troublesome
When to review or adjust approach

Trust earned, not claimed

We are GPhC-regulated, and our content is grounded in the licensed Mounjaro and Zepbound Summary of Product Characteristics documents (Eli Lilly) for tirzepatide characteristics, SURMOUNT trials (SURMOUNT-1 through SURMOUNT-5) for tirzepatide weight management evidence, SURPASS trials for glycaemic control evidence, SURMOUNT-4 for post-cessation weight regain data, head-to-head trials comparing tirzepatide and semaglutide, MHRA guidance on unlicensed compounded medicine manufacturing, GPhC standards for pharmacy compounding, and the real experience of patients managing weight after tirzepatide or semaglutide injection therapy.

If SLIM Films Tirzepatide aren’t the right answer for your situation, we’ll tell you honestly. After all, getting the right approach matters more than fulfilling a request.

How supply works

This is a compounded medicine. So the supply process has proper clinical steps.

How our service works

Complete the detailed weight management consultation on medicalmojo.co.uk
Our UK-qualified prescriber reviews your weight management history and current situation
The prescriber assesses whether tirzepatide is appropriate vs semaglutide alternatives
If approved, the prescriber issues a compounding order
APC Labs compounds your specific supply under GPhC-regulated compounding manufacturing
Your order is dispatched in plain, discreet packaging
Free prescriber support is available throughout treatment
Regular review to assess response and consider adjustments

When other options might suit better

If SLIM Films Tirzepatide aren’t right, we’ll explain why. Other options may include:

SLIM Films Semaglutide (1mg or 2mg) — for GLP-1-only mechanism
Continued Mounjaro injections at maintenance dose
Continued Wegovy injections (semaglutide alternative)
Reduced-dose weekly injections
Extended interval injection (every 2 weeks or monthly)
Rybelsus oral tablets (semaglutide alternative)
THIN sublingual sprays with tirzepatide (Medical Mojo alternative buccal option)
Non-GLP-1 maintenance approaches (orlistat, naltrexone/bupropion)
Structured behavioural interventions
Dietary approaches (Mediterranean diet, low-carb approaches)
Complete lifestyle-only maintenance
Specialist obesity medicine referral for complex cases
Bariatric surgery consideration for eligible patients not maintaining

Active ingredient

Each SLIM Film contains:

Tirzepatide 5mg (dual GIP and GLP-1 receptor agonist)
Menthol (permeation enhancer)
Novafilm base (mucoadhesive film-forming excipient, suitable for vegetarians)

Why tirzepatide

Tirzepatide is the first dual GIP/GLP-1 receptor agonist:

Synthetic peptide with agonist activity at both GIP and GLP-1 receptors
Long half-life (approximately 5 days)
Allows weekly rather than daily dosing
Effects on appetite regulation, gastric emptying, and glucose metabolism
Additional metabolic effects through GIP receptor engagement
Licensed as Mounjaro for type 2 diabetes and weight management (Eli Lilly)
Also licensed as Zepbound for weight management in some markets
SURMOUNT trials (SURMOUNT-1 through SURMOUNT-5) demonstrated efficacy in weight management
SURPASS trials demonstrated glycaemic control efficacy
Head-to-head trials often show greater weight loss than semaglutide
Well-characterised safety profile from ongoing post-marketing surveillance

In short, tirzepatide represents the newest generation of incretin-based therapies. After all, adding GIP receptor engagement to GLP-1 receptor engagement produces meaningfully different pharmacology — reflected in the trial data showing consistently greater weight loss than semaglutide.

The GIP receptor difference

Understanding what GIP receptor engagement adds:

GIP is glucose-dependent insulinotropic polypeptide, one of two main incretin hormones
GIP receptor engagement enhances insulin secretion in response to glucose
May improve energy expenditure through effects on adipose tissue
May improve tolerability of GLP-1 receptor activation
The combination provides broader metabolic effects than GLP-1 alone
Clinical translation: greater weight loss and often better GI tolerability in head-to-head data

So tirzepatide isn't just a stronger GLP-1 agonist — it's a different mechanism entirely. This matters when choosing between semaglutide and tirzepatide alternatives.

Why the 5mg strength

The 5mg dose reflects clinical positioning:

Corresponds to the standard maintenance dose used in Mounjaro injections (5mg weekly)
Below the higher weekly injectable doses used for maximum weight loss (10mg, 15mg)
Positioned as ongoing support rather than active weight loss dosing
Accounts for likely variability in buccal absorption compared to subcutaneous injection
Allows once or twice weekly dosing based on individual response
Provides meaningful dual receptor activity
Balances effect with tolerability for ongoing use

After all, buccal absorption isn't equivalent to subcutaneous injection. So the 5mg strength reflects appropriate positioning for the delivery route and clinical scenarios this product fits.

Why the buccal film format

The buccal route offers the same practical advantages as semaglutide SLIM Films:

Needle-free — no injection technique required
No cold chain — films stable at room temperature (important for Mounjaro-equivalent users, as Mounjaro requires refrigeration)
Portable — fits in a pocket or handbag
Discreet — usable in most settings without attracting attention
Bypasses gastric acid and digestive enzymes that would degrade tirzepatide
Avoids first-pass hepatic metabolism
Mucoadhesive coating allows prolonged contact with buccal mucosa for absorption
Rapid dissolve — films typically dissolve within minutes
No swallowing required — suitable for patients with dysphagia
Doesn't require water or food

In short, the buccal route addresses the practical barriers many patients face with injectable tirzepatide — needle discomfort, refrigeration requirements, injection technique anxiety, and the routine burden of weekly injection preparation. So while it doesn't replace injections for active weight loss, it offers a genuinely different practical profile for patients wanting ongoing tirzepatide-mechanism support.

Why menthol as permeation enhancer

Menthol serves the same specific pharmaceutical function as in semaglutide SLIM Films:

Enhances permeability of the buccal mucosa
Increases absorption of the tirzepatide through the buccal tissue
Well-established as a permeation enhancer in oral and mucosal drug delivery
Provides mild pleasant taste
Provides mild sensory feedback confirming film placement
Recognised as safe in this application

After all, tirzepatide is a large peptide molecule. Without permeation enhancement, buccal absorption would be limited. So menthol isn't just flavouring — it's functional formulation.

Why Novafilm base

Novafilm is a proprietary mucoadhesive film-forming platform:

Adheres to the buccal mucosa on contact
Prevents film displacement during dissolution
Provides sustained release of active over the dissolution period
Suitable for vegetarians (contains no animal-derived ingredients)
Well-tolerated on the buccal mucosa
Dissolves cleanly without residue
Compatible with menthol permeation enhancement

Other ingredients

Additional excipients in the Novafilm base support film integrity, adhesion, and controlled dissolution.

Complete excipients list is provided with each supply. So mention any known allergies or sensitivities during your consultation.

Pack details

SLIM Films Tirzepatide 5mg come as:

Individually foil-wrapped single-dose films
Typically supplied in packs matching prescribed frequency (4 or 8 film packs)
Amber blister backing to protect from light
Each film is single-use
Sealed until use
Clearly distinguished from semaglutide SLIM Films by packaging to prevent product confusion

How they're made

Important transparency points:

Compounded to prescriber order at APC Labs Ltd (GPhC 9012301)
Made under GPhC compounding manufacturing standards
Tirzepatide sourced from approved API supplier
Quality control includes content uniformity, dissolution, and microbial testing
Room temperature storage suitable
Shelf life determined by stability data
Batch documentation retained per compounding manufacturing standards

After all, this is compounded rather than industrially manufactured. So the regulatory pathway is genuinely different from licensed products like Mounjaro, and being clear about that matters.

What are SLIM Films Tirzepatide 5mg for?

SLIM Films Tirzepatide 5mg are designed for adults who need tirzepatide's dual GIP/GLP-1 receptor engagement in a needle-free format. So the target scenarios include patients transitioning off Mounjaro injections who want ongoing tirzepatide-mechanism support without needles, patients whose response to semaglutide has been insufficient and who may benefit from dual receptor engagement, and patients with needle phobia who specifically need tirzepatide's mechanism rather than semaglutide alternatives. As a result, they fit specific clinical scenarios where the tirzepatide mechanism itself matters.

Who might SLIM Films Tirzepatide 5mg suit?

This product may suit:

Adults transitioning off Mounjaro (tirzepatide) injection therapy
Adults who have had better response to tirzepatide than semaglutide
Adults whose semaglutide response has been insufficient
Adults specifically wanting the dual GIP/GLP-1 mechanism
Adults with significant food noise return after stopping tirzepatide injections
Adults with type 2 diabetes needing GLP-1 support with additional glycaemic benefits
Adults with needle phobia needing tirzepatide-mechanism support
Adults who dislike the practical routine of weekly injections
Adults committed to lifestyle changes alongside pharmacological support
Adults without contraindicating conditions
Adults tolerating GLP-1/GIP gastrointestinal effects
Adults understanding this is an unlicensed compounded medicine
Adults engaged with prescriber-led review and monitoring

What SLIM Films Tirzepatide 5mg may help with

Based on the pharmacology of tirzepatide and the compounded buccal positioning:

Ongoing appetite regulation via dual GIP/GLP-1 mechanism
Reduction of food noise (intrusive thoughts about food)
Snack prevention through stronger satiety signalling
Support during transition off Mounjaro injections
Glycaemic support in patients with type 2 diabetes
Reduced portion sizes at meals through earlier satiety
Support for patients who respond better to tirzepatide than semaglutide
Ongoing needle-free dual receptor engagement

Important honesty point: SLIM Films Tirzepatide 5mg support weight management — they don't guarantee it. After all, weight regulation is genuinely multifactorial. Lifestyle changes (dietary patterns, physical activity, sleep, stress management) remain the foundation of long-term outcomes. Pharmacological support helps, but it doesn't replace the underlying work. Realistic expectations matter.

What SLIM Films Tirzepatide 5mg don't claim to do

Honest framing matters:

They don't produce the active weight loss effect of full-dose weekly Mounjaro injections (5-15mg)
They don't guarantee weight loss or prevention of weight regain
They don't replace the need for dietary changes and physical activity
They don't address underlying causes of weight gain
They don't work overnight — steady state builds over weeks
They don't treat type 2 diabetes as a licensed indication
They don't work in medullary thyroid cancer or MEN2 syndrome — contraindicated
They don't have the extensive clinical trial evidence of licensed injectable formulations
They aren't automatically better than semaglutide alternatives — mechanism preference varies by patient

How SLIM Films Tirzepatide 5mg work

Understanding the dual mechanism helps explain both what to expect and why tirzepatide differs meaningfully from semaglutide.

The dual receptor mechanism

Tirzepatide targets two receptor systems:

Binds to GLP-1 receptors — same as semaglutide
Also binds to GIP receptors — unique to tirzepatide in this class
GLP-1 activation reduces appetite, slows gastric emptying, enhances glucose-dependent insulin release
GIP activation enhances insulin secretion, may affect adipose tissue metabolism
Combined effect: broader metabolic impact than GLP-1 alone
Clinical translation: greater weight loss than GLP-1-only agonists in head-to-head studies
GIP component may improve tolerability of GLP-1 activation for some patients

How the buccal film works

Film placed against inner cheek mucosa
Mucoadhesive Novafilm base attaches to buccal tissue
Film begins to hydrate from saliva
Menthol enhances permeability of buccal mucosa
Tirzepatide gradually released as film dissolves
Absorbed through buccal mucosa into systemic circulation
Bypasses gastric acid and digestive enzymes entirely
Bypasses first-pass hepatic metabolism
Reaches GLP-1 and GIP receptors throughout the body
Effects on appetite, gastric emptying, and glucose develop over hours to days

In short, buccal delivery of tirzepatide is a novel delivery approach for a novel dual receptor active. After all, this is why traditional tirzepatide delivery has been injection-based — peptides don't survive gastric passage.

Why weekly (rather than daily) dosing

Tirzepatide's pharmacology allows infrequent dosing:

Long half-life (approximately 5 days)
Slightly shorter half-life than semaglutide (approximately 7 days)
Steady state plasma concentrations achieved over 4-5 weeks
Weekly dosing gives smooth plasma profile
Twice-weekly dosing gives higher steady state
Buccal absorption dosing accounts for likely bioavailability differences
Individual response variability means dose frequency may be adjusted

Onset timeline

What to expect:

First week: no obvious effect for most patients; possible early GI side effects
Weeks 2-4: appetite regulation may begin to develop
Weeks 4-8: steady state plasma concentrations achieved
Beyond 8 weeks: full effect established
Individual variation is significant
Some patients notice food noise reduction earlier than with semaglutide alternatives

How to use SLIM Films Tirzepatide 5mg

Correct technique matters for effectiveness. So take a few minutes to understand the technique before your first film.

Standard technique

Wash your hands thoroughly
Remove one film from its foil pouch immediately before use
Handle the film by the edges, don't touch the central area if possible
Open your mouth and dry the inner cheek surface slightly with your tongue
Place the film against the inner cheek, pressing lightly for a few seconds
The mucoadhesive base will attach to the cheek
Leave the film in place, don't chew or swallow
The film will dissolve over minutes
Avoid eating or drinking for 15-30 minutes after
Don't rinse your mouth immediately after

Practical tips

Alternate cheeks between doses to avoid local irritation
Best applied at a consistent time (allows routine)
Doesn't need to be at any particular time relative to meals
Menthol sensation confirms placement — this is normal
If film comes loose before dissolution, discuss with prescriber

Frequency

Typical starting frequency: one film per week
Can increase to two films per week if prescriber advises and initial dose is well-tolerated
Space by at least 3 days between doses
Follow prescriber's specific instructions
Tirzepatide GI effects can be prominent — allow adaptation time

What to combine with

Comprehensive support often needs multiple elements:

Continued attention to dietary patterns
Regular physical activity
Adequate sleep
Stress management
Regular self-monitoring (weight, measurements, or wellbeing markers)
Behavioural strategies for high-risk situations
Support networks and accountability

What to avoid

Chewing or swallowing the film
Eating or drinking immediately after application
Rinsing your mouth immediately after
Combining with any other GLP-1 or GIP/GLP-1 formulations
Using during pregnancy or breastfeeding
Using without prescriber review during treatment

If a film comes loose

If it comes off before dissolving, discuss with prescriber
Don't automatically use another one
Note timing and circumstances for pharmacist advice

Storage

Store at room temperature
Keep in original packaging
Away from direct heat and moisture
Keep out of sight and reach of children
Use by expiry date on packaging
Store separately from any semaglutide SLIM Films to prevent product confusion

Warnings and precautions

Tirzepatide has important safety considerations. So the warnings section is longer and more important than for many products.

Don't use SLIM Films Tirzepatide if you

Have personal or family history of medullary thyroid carcinoma
Have multiple endocrine neoplasia syndrome type 2 (MEN2)
Have had pancreatitis
Have severe gastrointestinal disease including gastroparesis
Have severe hepatic impairment
Have severe renal impairment (end-stage)
Are pregnant or planning pregnancy
Are breastfeeding
Have known allergy to tirzepatide or any excipient
Have active oral pathology that would prevent absorption
Have active eating disorder

The pancreatitis warning

Rare but serious:

Incretin-based therapies including tirzepatide have been associated with pancreatitis in post-marketing data
Absolute risk is low but real
Previous pancreatitis is a contraindication
Symptoms: severe upper abdominal pain radiating to back, nausea, vomiting
Stop treatment and seek urgent medical assessment if pancreatitis suspected

The thyroid warning

Contraindication basis:

Rodent studies showed thyroid C-cell tumours with incretin therapies
Human relevance unclear but precautionary contraindication in medullary thyroid cancer and MEN2
Family history of medullary thyroid cancer is a contraindication
New neck lumps or thyroid symptoms during treatment need assessment

The gallbladder warning

Increased risk documented:

Incretin therapies increase risk of gallstone-related events
Weight loss itself also increases gallstone risk
Symptoms: right upper abdominal pain, particularly after fatty meals
Active gallbladder disease is a relative contraindication

The diabetic retinopathy warning

Relevant for diabetics:

Rapid glycaemic changes can worsen diabetic retinopathy
Proliferative retinopathy is a relative contraindication
Retinal review recommended before starting in diabetics with retinopathy

The eating disorder consideration

Important safeguard:

Active eating disorders (anorexia, bulimia) are contraindications
Past eating disorders warrant specialist input before incretin use
Body image dysmorphia warrants careful assessment
Prescriber screens for eating disorder markers

The prominent GI effects consideration

Tirzepatide-specific:

Nausea, vomiting, diarrhoea, and constipation can be prominent especially initially
Often manageable but sometimes limiting
May settle over weeks as body adjusts
Small frequent meals help
Adequate hydration important
If severe or persistent, discuss with prescriber

Use with care if you

Have mild-to-moderate renal impairment
Have mild-to-moderate hepatic impairment
Have gastroparesis or slowed gastric emptying
Have gastro-oesophageal reflux disease
Have type 1 diabetes (tirzepatide not licensed for this)
Are on insulin or sulphonylurea (hypoglycaemia risk)
Are over 75 years old (limited data in very elderly)
Have had bariatric surgery (specialist input recommended)
Have not tolerated GLP-1 therapies previously

Pregnancy and breastfeeding

Not for use during pregnancy or planning pregnancy
Not for use during breastfeeding
Stop treatment at least 2 months before planned conception
Effective contraception during use in women of childbearing age
Tirzepatide may reduce efficacy of oral hormonal contraceptives — consider alternative contraception

The oral contraceptive interaction

Important for women of childbearing age:

Tirzepatide slows gastric emptying, which can reduce absorption of oral contraceptives
This is a documented interaction with the injectable form
Buccal delivery may have less impact but caution advised
Consider non-oral contraceptive methods (implant, IUD, injection) while using tirzepatide
Discuss with prescriber if oral contraception is your only method

Driving and machinery

Generally doesn't affect driving:

SLIM Films don't typically affect driving
Hypoglycaemia risk if used alongside diabetic medications
Nausea during initial dosing may affect concentration

When to seek urgent medical help

Severe upper abdominal pain (possible pancreatitis)
Right upper abdominal pain (possible gallstones)
Signs of severe allergic reaction (facial swelling, breathing difficulty)
New neck lumps or persistent hoarseness
Persistent severe vomiting
Signs of dehydration
Vision changes (in diabetics)

Side effects

Tirzepatide has a well-characterised side effect profile from licensed injectable Mounjaro and Zepbound formulations. GI effects can be prominent, particularly during initial treatment.

Common side effects

Nausea (often prominent especially initially)
Vomiting
Diarrhoea (more common with tirzepatide than semaglutide)
Constipation
Abdominal pain
Dyspepsia (indigestion)
Reduced appetite
Fatigue
Headache
Local mucosal irritation (buccal-specific)
Menthol taste sensation

Less common side effects

Hypoglycaemia (if used alongside diabetic medications)
Belching
Flatulence
Bloating
Gastro-oesophageal reflux
Local reactions at buccal site
Altered taste
Dizziness
Hair loss (documented with tirzepatide)

Rare side effects

Acute pancreatitis
Gallbladder events (gallstones, cholecystitis)
Acute kidney injury (associated with dehydration from vomiting/diarrhoea)
Diabetic retinopathy worsening
Allergic reactions
Elevated pancreatic enzymes

Very rare side effects

Severe allergic reactions (anaphylaxis)
Angioedema

The GI symptoms question

Prominent but usually manageable:

Nausea and other GI symptoms are the most common side effects with tirzepatide
Diarrhoea appears more common with tirzepatide than with semaglutide
Typically improve over weeks as the body adjusts
Small frequent meals help
Avoiding high-fat meals helps
Adequate hydration important
If severe or persistent, discuss with prescriber

The hair loss question

Documented but usually reversible:

Hair thinning or shedding has been reported with tirzepatide
More common than with semaglutide
Typically related to rapid weight loss rather than tirzepatide itself
Usually reversible with time
Ensuring adequate nutrition (protein, iron, biotin, zinc) helps
Discuss with prescriber if concerning

Stop and seek urgent medical help if

Severe upper abdominal pain
Signs of severe allergic reaction
Persistent severe vomiting causing dehydration
Vision changes
New neck lumps

Yellow Card reporting

If you experience any side effects, you can report them via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Reporting side effects helps improve safety information for all patients.

Drug interactions

Tirzepatide has several important interactions to consider.

Interactions requiring care

Insulin — hypoglycaemia risk, may need insulin dose reduction
Sulphonylureas (gliclazide, glimepiride) — hypoglycaemia risk
Oral medications generally — slowed gastric emptying may affect absorption
Oral hormonal contraceptives — reduced efficacy documented, consider alternative methods
Warfarin — check INR after starting or adjusting
Levothyroxine — timing may need adjustment
Antibiotics — timing may need adjustment

Not usually clinically significant

Metformin — often used together
SGLT2 inhibitors — often used together
DPP-4 inhibitors — usually not combined (redundant mechanism)
Statins — generally safe
Antihypertensives — generally safe
Most antibiotics — timing may need review

Combinations to avoid

Other GLP-1 receptor agonists (Wegovy, Ozempic, Rybelsus, Saxenda) — don't combine
Other tirzepatide products (Mounjaro, Zepbound) — don't combine
SLIM Films semaglutide — don't combine with tirzepatide (choose one)
DPP-4 inhibitors (sitagliptin, linagliptin) — redundant mechanism

Alcohol

Some caution needed:

Alcohol can worsen hypoglycaemia risk in diabetics
May increase GI side effects
Also affects appetite regulation
Moderation advised

Frequently asked questions

How is tirzepatide different from semaglutide?

Different mechanisms:

Semaglutide: GLP-1 receptor agonist only
Tirzepatide: dual GLP-1 and GIP receptor agonist
Tirzepatide often produces greater weight loss in head-to-head trials
GI side effects (particularly diarrhoea) may be more prominent with tirzepatide
Semaglutide has longer post-marketing safety history
Individual response varies — some patients respond better to one than the other

Should I use tirzepatide or semaglutide SLIM Films?

Depends on your situation:

Previous good response to Mounjaro suggests tirzepatide continuation
Previous good response to Wegovy/Ozempic suggests semaglutide continuation
Insufficient response to semaglutide may suggest tirzepatide trial
Prescriber assessment guides the decision
Don't self-select based on 'newest' or 'strongest' assumptions

Can I switch between tirzepatide and semaglutide SLIM Films?

Yes, with prescriber guidance:

Switching between GLP-1 and dual GIP/GLP-1 mechanisms is common in clinical practice
Wash-out periods may be needed depending on timing
Don't combine tirzepatide and semaglutide SLIM Films — choose one
Prescriber discusses timing of switches

Will tirzepatide cause more nausea than semaglutide?

Often yes, especially initially:

Tirzepatide GI effects can be more prominent than semaglutide
Diarrhoea appears more common with tirzepatide
Nausea usually improves over weeks as body adjusts
Small frequent meals help
Avoiding high-fat meals helps

Can I use for active weight loss?

Not the typical positioning:

SLIM Films Tirzepatide 5mg aren't equivalent to full 5-15mg Mounjaro injections
For active weight loss, injection therapy usually fits better
SLIM Films Tirzepatide fit ongoing tirzepatide-mechanism support
Some patients may see modest additional weight loss
Realistic expectations matter

How fast do they work?

Gradual effect:

Steady state builds over 4-5 weeks
Some patients notice food noise reduction earlier
Full effect typically 6-8 weeks
Not for acute effect

Will tirzepatide affect my contraception?

Important interaction:

Tirzepatide may reduce efficacy of oral hormonal contraceptives
This is documented with the injectable form
Buccal delivery may have less impact but caution advised
Consider non-oral contraception (implant, IUD, injection)
Discuss with prescriber if oral contraception is your only method

Can it cause hair loss?

Reported but usually reversible:

Hair thinning has been reported with tirzepatide
More common than with semaglutide
Usually related to rapid weight loss rather than the medication itself
Ensuring adequate protein, iron, zinc, biotin intake helps
Typically reversible
Our Gro range hair loss products may help if it becomes an issue

Can I combine with injections?

No, don't combine:

Don't combine SLIM Films with any other GLP-1 or GIP/GLP-1 formulation
This would cause excessive dosing
Choose one approach at a time

Can I use in pregnancy?

No:

Tirzepatide contraindicated in pregnancy
Stop treatment at least 2 months before planned conception
Effective contraception during use
Contact prescriber if pregnancy occurs during treatment

What if I get severe abdominal pain?

Stop and seek assessment:

Severe upper abdominal pain radiating to the back can indicate pancreatitis
Right upper abdominal pain can indicate gallstones
Both need urgent medical assessment
Stop SLIM Films pending assessment

How should I store them?

Room temperature
In original packaging
Away from direct heat and moisture
Keep out of reach of children
Use by expiry date
Store separately from semaglutide SLIM Films to prevent product confusion

Is my packaging discreet?

Plain packaging with no mention of contents
Suitable for delivery to home or workplace

How do I order from Medical Mojo?

Complete the weight management consultation on medicalmojo.co.uk. Our prescriber will review your treatment history and current situation, then arrange compounding by APC Labs if suitable. Your order goes out in plain, discreet packaging with support available throughout your treatment.

Disclaimer

This page is for information only and isn't a substitute for personal medical advice.
SLIM Films Tirzepatide 5mg are an unlicensed compounded medicine containing tirzepatide, made available under the compounding pathway based on individual prescriber judgement.
Tirzepatide is contraindicated in medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous pancreatitis, pregnancy, and breastfeeding.
Prescriber assessment before use is essential. Tirzepatide GI side effects (particularly nausea, vomiting, diarrhoea) can be prominent especially initially. Tirzepatide may reduce efficacy of oral hormonal contraceptives — alternative contraception may be needed.
Signs of pancreatitis (severe upper abdominal pain radiating to back with nausea and vomiting) need urgent medical assessment.
Signs of severe allergic reaction (facial swelling, breathing difficulty, widespread rash) need immediate medical attention (999). SLIM Films
Tirzepatide are positioned for ongoing tirzepatide-mechanism support, not for active weight loss — licensed injectable products (Mounjaro, Zepbound) typically fit active treatment phase better.
This product should be used alongside comprehensive lifestyle approaches to weight management.

References

[1] Wilding, J.P.H. et al. (2022) ‘Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension’, Diabetes, Obesity and Metabolism, 24(8), pp. 1553–1564. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/ (Accessed: 4 July 2026).

[2] Aronne, L.J. et al. (2024) ‘Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial’, JAMA, 331(1), pp. 38–48. Available at: https://doi.org/10.1001/jama.2023.24945 (Accessed: 4 July 2026).

[3] Rubino, D. et al. (2021) ‘Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial’, JAMA, 325(14), pp. 1414–1425. Available at: https://doi.org/10.1001/jama.2021.3224 (Accessed: 4 July 2026).

[4] National Institute for Health and Care Excellence (2023) Semaglutide for managing overweight and obesity (TA875). Available at: https://www.nice.org.uk/guidance/ta875 (Accessed: 4 July 2026).

[5] National Institute for Health and Care Excellence (2024) Tirzepatide for managing overweight and obesity (TA1026). Available at: https://www.nice.org.uk/guidance/ta1026 (Accessed: 4 July 2026).

[6] National Health Service (2023) Obesity. Available at: https://www.nhs.uk/conditions/obesity/ (Accessed: 4 July 2026).

Get medicines tailored to you

Conditions

Treatments

Care and policies